Table Graph
      published meta-analysis   sensitivity analysis   studies

Vitamins in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsCOVIT-TRIAL, 2022 0.54 [0.22; 1.34] 0.54[0.22; 1.34]COVIT-TRIAL, 202210%254NAnot evaluable death D28detailed resultsCOVIT-TRIAL, 2022 0.89 [0.45; 1.75] 0.89[0.45; 1.75]COVIT-TRIAL, 202210%252NAnot evaluable deathsdetailed resultsCOVIT-TRIAL, 2022 0.89 [0.45; 1.75] 0.89[0.45; 1.75]COVIT-TRIAL, 202210%252NAnot evaluable viral clearance detailed resultsRastogi, 2020 6.33 [1.54; 26.00] 6.33[1.54; 26.00]Rastogi, 202010%40NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-06-13 11:29 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 1244,523,885,734,1439 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons